The United Laboratories International Holdings Limited (3933.HK)
HKD 13.94
(0.29%)
HKD 13.94
(0.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.26 Billion CNY | -1.2% |
| 2022 | 8.37 Billion CNY | 19.72% |
| 2021 | 6.99 Billion CNY | 10.07% |
| 2020 | 6.35 Billion CNY | -29.64% |
| 2019 | 9.02 Billion CNY | 6.46% |
| 2018 | 8.48 Billion CNY | -2.19% |
| 2017 | 8.67 Billion CNY | -9.86% |
| 2016 | 9.61 Billion CNY | 7.41% |
| 2015 | 8.95 Billion CNY | -6.3% |
| 2014 | 9.55 Billion CNY | -6.69% |
| 2013 | 10.24 Billion CNY | 26.61% |
| 2012 | 8.08 Billion CNY | 49.45% |
| 2011 | 5.41 Billion CNY | 41.21% |
| 2010 | 3.83 Billion CNY | 2.03% |
| 2009 | 3.75 Billion CNY | 27.22% |
| 2008 | 2.95 Billion CNY | 37.2% |
| 2007 | 2.15 Billion CNY | -10.58% |
| 2006 | 2.4 Billion CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.25 Billion CNY | 0.0% |
| 2023 Q2 | 8.23 Billion CNY | 0.0% |
| 2023 Q4 | 8.26 Billion CNY | 0.0% |
| 2023 FY | 8.26 Billion CNY | -1.2% |
| 2022 Q4 | 8.37 Billion CNY | 0.0% |
| 2022 FY | 8.37 Billion CNY | 19.72% |
| 2022 Q2 | 7.6 Billion CNY | 0.0% |
| 2021 Q2 | 6.76 Billion CNY | 0.0% |
| 2021 FY | 6.99 Billion CNY | 10.07% |
| 2021 Q4 | 6.99 Billion CNY | 0.0% |
| 2020 Q2 | 7.29 Billion CNY | 0.0% |
| 2020 Q4 | 6.35 Billion CNY | 0.0% |
| 2020 FY | 6.35 Billion CNY | -29.64% |
| 2019 Q2 | 8.94 Billion CNY | 0.0% |
| 2019 FY | 9.02 Billion CNY | 6.46% |
| 2019 Q4 | 9.02 Billion CNY | 0.0% |
| 2018 Q2 | 8.88 Billion CNY | 0.0% |
| 2018 Q4 | 8.48 Billion CNY | 0.0% |
| 2018 FY | 8.48 Billion CNY | -2.19% |
| 2017 FY | 8.67 Billion CNY | -9.86% |
| 2017 Q4 | 8.67 Billion CNY | 0.0% |
| 2017 Q2 | 9.31 Billion CNY | 0.0% |
| 2016 Q4 | 9.61 Billion CNY | 0.0% |
| 2016 FY | 9.61 Billion CNY | 7.41% |
| 2016 Q2 | 9.07 Billion CNY | 0.0% |
| 2015 FY | 8.95 Billion CNY | -6.3% |
| 2015 Q2 | 9.25 Billion CNY | 0.0% |
| 2015 Q4 | 8.95 Billion CNY | 0.0% |
| 2014 Q2 | 10 Billion CNY | 0.0% |
| 2014 Q4 | 9.55 Billion CNY | 0.0% |
| 2014 FY | 9.55 Billion CNY | -6.69% |
| 2013 Q2 | 9.01 Billion CNY | 0.0% |
| 2013 FY | 10.24 Billion CNY | 26.61% |
| 2013 Q4 | 10.25 Billion CNY | 0.0% |
| 2012 Q2 | 6.1 Billion CNY | 0.0% |
| 2012 Q4 | 8.08 Billion CNY | 0.0% |
| 2012 FY | 8.08 Billion CNY | 49.45% |
| 2011 Q4 | 5.41 Billion CNY | 0.0% |
| 2011 Q2 | 4.55 Billion CNY | 0.0% |
| 2011 FY | 5.41 Billion CNY | 41.21% |
| 2010 Q4 | 3.83 Billion CNY | 0.0% |
| 2010 FY | 3.83 Billion CNY | 2.03% |
| 2010 Q2 | 4.19 Billion CNY | 0.0% |
| 2009 Q4 | 3.75 Billion CNY | 0.0% |
| 2009 FY | 3.75 Billion CNY | 27.22% |
| 2008 FY | 2.95 Billion CNY | 37.2% |
| 2007 FY | 2.15 Billion CNY | -10.58% |
| 2006 FY | 2.4 Billion CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -5712.093% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | -14.145% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -4752.83% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -1065.295% |
| Qianhai Health Holdings Limited | 94 Million HKD | -8697.126% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | -789.134% |
| Essex Bio-Technology Limited | 903.78 Million HKD | -814.996% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -1142.816% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -1099.094% |
| SSY Group Limited | 4.49 Billion HKD | -84.016% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -2154.804% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | -658.332% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 95.091% |